circRNA basic information
circBase ID: hsa_circ_0072979
Name: hsa_circ_FCHO2
Synonym: circFCHO2
Host Gene: FCHO2
Genomic location(hg19): chr5:72374006-72378652:+
Genomic location(hg38): chr5:73078179-73082825:+
Subcellular localization: cytoplasm; exosome
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
 0001056
MONDO name: gastric cancer
Disease details: gastric cancer
Disease DO ID:
 10534
Disease MeSH ID:
 -
Disease NCIt ID:
 C9331
Disease ICD11 ID:
 1397617262
Disease OMIM ID:
 613659
Species: Human
Species details: Homo sapiens
Tissue specimen:

tumor tissues; corresponding paired adjacent noncancerous tissues; blood; serum exosomes; lung tissues
Cell lines:

GES-1; MKN28; HGC-27; MKN45; AGS
In vivo animal model:

cell line-derived xenograft
circRNA-disease information
Expression pattern:
UP
Associated gene: JAK1, STAT3, p-STAT3
Associated microRNA: miR-194-5p
Biological function: circFCHO2 acts as an oncogene in gastric cancer; it promotes GC cell proliferation, invasion, angiogenesis, cancer stem cell characteristics, in vivo tumor growth, lung metastasis and lymphatic metastasis.
Molecular mechanism: circFCHO2 sponges miR-194-5p, suppresses miR-194-5p expression, increases JAK1 expression and activates the JAK1/STAT3 signaling pathway.
Biological pathway or process:

JAK/STAT (promotes); proliferation (promotes); invasion (promotes); angiogenesis (promotes); stemness (promotes); metastasis (promotes); ceRNA regulation (promotes)
Detected method:
Q
Validation methods:

Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; RT-qPCR; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Transwell Assay; Tube Formation Assay; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); Western Blot; Survival Analysis; ROC Analysis; Bioinformatics Analysis
Clinical significance:

High circFCHO2 expression is associated with poor prognosis, poor 60-month survival, lower metastasis-free survival, lymph node metastasis and lung metastasis; serum exosomal circFCHO2 may serve as a diagnostic marker for GC.
Description:

circFCHO2 is up-regulated in gastric cancer tissues, cell lines and serum exosomes, and high expression is associated with poor clinical outcome and metastasis. Functionally, circFCHO2 promotes GC proliferation, invasion, angiogenesis, stem-like properties, tumor growth and metastasis. Mechanistically, it acts as a cytoplasmic miR-194-5p sponge to increase JAK1 and activate the JAK1/STAT3 pathway, and serum exosomal circFCHO2 may serve as a diagnostic marker.
Confidence score:

0.8921
Other information
Title:

circFCHO2 promotes gastric cancer progression by activating the JAK1/STAT3 pathway via sponging miR-194-5p.

Journal: Cell cycle (Georgetown, Tex.)
Published: 2022
PubMed ID: 35708677
Study type:

combined biological and clinical study
Data availability: All the data used to support the findings of this study are included within the article.
Code availability: -